• KMT2A-rearranged ALL
• Advances in Ph-like ALL
• Revisiting specific ALL subsets
• New biological insights in ALL
• Ph-positive ALL
• Therapeutic Challenges in Childhood ALL
• Antibody-based ALL Therapies
• CAR T-cells & Stem Cell Transplantation
• Precision Medicine in ALL
Stay tuned: registration & abstract submission are opening soon!
About the Conference:
Major recent advances in the knowledge of the biological underpinning of Acute Lymphoblastic Leukaemia (ALL) include the comprehensive description of B-cell precursor and T-cell ALL genomic landscapes, the identification of new potentially druggable disease subsets and the discovery of predisposing, preleukaemic events.
At the same time, the clinical management of the disease has improved in both children and adults thanks to the routine monitoring of measurable residual disease (MRD), the administration of intensified risk-adapted chemotherapy, the introduction of targeted therapies and antibodies, and the remarkable efficacy of antibody-drug conjugates (ADCs), bi-specific T-cell engager antibodies (BiTEs) and manufactured chimeric antigen receptor (CAR) T-cells.
This intense research activity has led to major improvements in patient outcome, while also providing important proofs of concept for the treatment of cancer in general. It has also made ALL
a fascinating disease to study.
The translational scientific programme of the 3rd Translational Research Conference on Acute Lymphoblastic Leukaemia is designed to provide ample time and opportunities for discussion with global authorities in the field.
The programme will include:
Plenary Sessions - Panel Discussions - Debates
Poster Walks - Meet the Expert Sessions - Keynote lectures
Take a look at the preliminary programme of #ESHALL2023:
For more information, click here!